BioCryst Pharmaceuticals and Idera Pharmaceuticals have struck a deal to combine into a single company focused on treatments for rare diseases.
The stock deal announced Monday calls for each share of Research Triangle Park, NC-based BioCryst (NASDAQ: BCRX) to be exchanged for 0.50 shares of the new company. Idera (NASDAQ: IDRA) shareholders will get 0.20 shares of the new company for each Idera share. When the merger closes, BioCryst shareholders will own 51.6 percent of the combined company, and Idera shareholders will own the remaining 48.4 percent.
The new company, which will be renamed after the merger closes, will… Read more »
UNDERWRITERS AND PARTNERS